Loading...
XNYS
PEN
Market cap11bUSD
May 02, Last price  
296.00USD
1D
1.43%
1Q
10.87%
Jan 2017
363.95%
IPO
640.00%
Name

Penumbra Inc

Chart & Performance

D1W1MN
P/E
818.07
P/S
9.60
EPS
0.36
Div Yield, %
Shrs. gr., 5y
1.60%
Rev. gr., 5y
16.89%
Revenues
1.19b
+12.86%
73,141,00088,848,000125,510,000186,095,000263,317,000333,764,000444,938,000547,405,000560,412,000747,590,000847,133,0001,058,522,0001,194,615,000
Net income
14m
-84.59%
1,958,0004,099,0002,245,0002,365,00014,814,0004,657,0006,601,00048,458,000-19,257,0002,623,000-2,002,00090,954,00014,012,000
CFO
168m
+73.10%
-3,396,000-6,389,000-22,279,000-12,807,00012,691,00028,808,00026,652,000-33,242,0009,502,000-55,661,00097,333,000168,481,000
Earnings
May 05, 2025

Profile

Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, BMX96, DDC, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; aspiration-based thrombectomy systems for vascular applications under the Indigo System brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names. In addition, the company offers microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand; and detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand, as well as immersive computer-based technologies and immersive therapeutics to promote health, motor function, and cognition under the Real Immersive System brand; and a complementary device for use with Ruby Coil and POD for vessel occlusion under the Packing Coil and Packing Coil LP brands. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.
IPO date
Sep 18, 2015
Employees
3,900
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
1,194,615
12.86%
1,058,522
24.95%
847,133
13.32%
Cost of revenue
534,403
966,756
841,051
Unusual Expense (Income)
NOPBT
660,212
91,766
6,082
NOPBT Margin
55.27%
8.67%
0.72%
Operating Taxes
6,857
(11,304)
5,894
Tax Rate
1.04%
96.91%
NOPAT
653,355
103,070
188
Net income
14,012
-84.59%
90,954
-4,643.16%
(2,002)
-176.32%
Dividends
Dividend yield
Proceeds from repurchase of equity
(100,387)
12,822
5,724
BB yield
1.08%
-0.13%
-0.07%
Debt
Debt current
14,590
26,868
11,953
Long-term debt
432,188
455,252
459,593
Deferred revenue
Other long-term liabilities
15,106
5,308
3,276
Net debt
106,647
212,872
283,516
Cash flow
Cash from operating activities
168,481
97,333
(55,661)
CAPEX
(21,182)
(15,213)
(19,298)
Cash from investing activities
77,624
(16,076)
54,790
Cash from financing activities
(87,006)
16,203
11,622
FCF
720,048
26,356
(185,007)
Balance
Cash
340,131
289,187
188,030
Long term investments
(19,939)
Excess cash
280,400
216,322
145,673
Stockholders' equity
54,199
131,746
35,818
Invested Capital
1,335,227
1,300,283
1,202,089
ROIC
49.58%
8.24%
0.02%
ROCE
47.52%
6.41%
0.49%
EV
Common stock shares outstanding
39,268
39,217
37,842
Price
237.48
-5.59%
251.54
13.07%
222.46
-22.57%
Market cap
9,325,373
-5.47%
9,864,535
17.18%
8,418,303
-22.65%
EV
9,432,020
10,077,407
8,701,819
EBITDA
683,914
119,023
30,403
EV/EBITDA
13.79
84.67
286.22
Interest
1,418
1,739
137
Interest/NOPBT
0.21%
1.90%
2.25%